Â鶹Éç

Amplyx Pharmaceuticals is developing a new class of antifungal medicine to overcome the limitations of existing therapeutic options. The companies two product candidates are Fosmanogepix (APX001), a novel antifungal agent being developed for the treatment of life-threatening fungal infections caused by pathogens such as Candida, Aspergillus and rare molds, and MAU868, a monoclonal antibody that potently neutralizes the BK virus, which causes significant morbidity and mortality in transplant patients.